About Apheon Biosciences
Apheon Biosciences is committed to help drive research innovation through cutting-edge molecular solutions and unwavering dedication to advancing immune-therapy research.
Our Mission
At Apheon, we are dedicated to accelerating the next generation of immunotherapies. By integrating our proprietary ApheGenixID™ platform with expert recombinant engineering, we unlock novel therapeutic opportunities for aggressive diseases and underserved conditions in women’s health.
Our mission is to bridge the gap between target discovery and clinical application. We provide pharmaceutical partners and research institutions with precision-engineered antibodies and high-value IP designed to advance the frontiers of molecular medicine. Whether through our internal pipeline or strategic service collaborations, we are committed to scientific rigor and the rapid delivery of transformative biological assets.
We invite you to explore our technology and discuss how our platform can fortify your development goals. Contact us today to discuss strategic partnerships and collaborative research opportunities.
Meet Our Research Team
William J. Belden, Ph.D.
President, CSO and Professor Emeritus
Bill provides the scientific leadership and strategic oversight required to advance Apheon’s proprietary programs and maximize the global potential of the ApheGenixID™ platform.
Tammy M. Joska, Ph.D.
Co-founder, Advisor, and Board Member
Tammy leverages her deep scientific background to serve as a key advisor and board member, guiding Apheon’s capital strategy and supporting the advancement of its proprietary research initiatives.
R. Michael Belden, M.D.
V.P of Strategic Initiatives.
Micheal brings over 30 years of clinical and surgical expertise in woman’s health and oversees the strategic integration of clinical insights into the company’s therapeutic development programs.
Core Services
Comprehensive solutions for advanced research
Precision Cloning and Recombinant Antibody Development
We offer a variety of cloning products and services to support academic and industry research and synthetic biology. Our precision approach ensures reliable, reproducible results for your most critical projects.
Disease Profiling/Immunotherapy Development
We profile disease states based on antigenicity, identifying biomarkers and generating biologic leads. Our comprehensive approach accelerates therapeutic discovery and development.
Scaling Discovery through ApheGenixID™
Our proprietary antigen identification and lead recovery engine transforms the complexity of immunotherapy into a repeatable, high-precision process, powering our internal pipeline and enabling our global partners to secure the next generation of clinical assets.
TAA Identification
High-resolution antigen discovery to identify exclusive, high-value targets for precision therapies.
Lead Recovery
Rapid isolation of high-affinity recombinant binders to accelerate transition to clinical candidates.
AI-Driven Optimization
In silico design and sequence refinement to maximize binding specificity and ensure superior IP protection.
Partner with Apheon
Building strong, mutually-beneficial relationships with like-minded organizations
Strategic Partnerships
Explore collaborative opportunities to advance immune-therapy research and development
Institution Portal
Join forces with our team to tackle complex molecular biology challenges